Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Neuropsychological Evaluation for Early Diagnosis of PSP

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03478124
Recruitment Status : Completed
First Posted : March 27, 2018
Last Update Posted : March 27, 2018
Sponsor:
Information provided by (Responsible Party):
Ospedale Generale Di Zona Moriggia-Pelascini

Study Description
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The aim of this study is to better understand the nature of the cognitive decline in Progressive Supranuclear Palsy, the time of its development and the relation with the other cardinal features of the disease.

Condition or disease Intervention/treatment
Progressive Supranuclear Palsy Cognitive Impairment Behavioral: Cognitive evaluation

Detailed Description:
Progressive Supranuclear Palsy (PSP) is a neurodegenerative disease characterized by vertical supranuclear gaze palsy, early balance dysfunction and falls. Tau-protein aggregation, mainly in the brainstem, is the disease hallmark. Because of the similarities with Parkinson's disease (PD), the diagnosis is made approximately 4 years after the symptoms onset. Cognitive deficits are a leading feature of PSP and they actually represent one of the four functional core domains in the revised diagnostic criteria. The aim of this study is to better understand the nature of this cognitive decline, the time of its development and the relation with the other cardinal features of the disease.
Study Design
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Observational
Actual Enrollment : 112 participants
Observational Model: Cohort
Time Perspective: Other
Official Title: The Role of the Neuropsychological Evaluation for Early Diagnosis of Progressive Supranuclear Palsy
Actual Study Start Date : January 1, 2016
Actual Primary Completion Date : March 1, 2018
Actual Study Completion Date : March 2, 2018

Resource links provided by the National Library of Medicine


Groups and Cohorts
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Group/Cohort Intervention/treatment
PSP patients
Patients suffering from Progressive Supranuclear Palsy (PSP)
 Behavioral: Cognitive evaluation
An extensive battery of neuropsychological and motor tests was assessed: MMSE, FAB, MoCA, WCST, Stroop Test, TMT-A and B, Verbal fluency Test, ROCF copy and delayed recall, RAVLT, 6MWT, TUG, BBS.
PD Patients
Patients suffering from Parkinson's disease (PD)
 Behavioral: Cognitive evaluation
An extensive battery of neuropsychological and motor tests was assessed: MMSE, FAB, MoCA, WCST, Stroop Test, TMT-A and B, Verbal fluency Test, ROCF copy and delayed recall, RAVLT, 6MWT, TUG, BBS.


Outcome Measures
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. MMSE [ Time Frame: 1 year ]
    Mini-Mental State Examination

  2. FAB [ Time Frame: 1 year ]
    Frontal Assessment Battery

  3. MoCA [ Time Frame: 1 year ]
    Montreal Cognitive Assessment

  4. WCST [ Time Frame: 1 year ]
    Wisconsin Card Sorting Test

  5. ST [ Time Frame: 1 year ]
    Stroop Test

  6. TMT-A and B [ Time Frame: 1 year ]
    Trail Making Test Parts A & B

  7. VFT [ Time Frame: 1 year ]
    Verbal fluency Test

  8. ROCF copy and delayed recall [ Time Frame: 1 year ]
    Rey-Osterrieth complex figure test copy and delayed recall

  9. RAVLT [ Time Frame: 1 year ]
    Rey Auditory Verbal Learning Test


Secondary Outcome Measures :
  1. 6MWT [ Time Frame: 1 year ]
    6 Minute Walk Test

  2. TUG [ Time Frame: 1 year ]
    Timed Up and Go Test

  3. BBS [ Time Frame: 1 year ]
    Berg Balance Scale


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sampling Method:   Probability Sample
Study Population
56 PSP patients (PSPp) and 56 PD patients (PDp) were enrolled and matched for sex, age and disease duration.
Criteria

Inclusion Criteria:

  • Patients fulfilling the criteria for idiopathic PD
  • Patients fulfilling the criteria for PSP

Exclusion Criteria:

  • Any other neurodegenerative disorders or medical conditions different from PD / PSP
Contacts and Locations
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03478124


Sponsors and Collaborators
Ospedale Generale Di Zona Moriggia-Pelascini
Investigators
Layout table for investigator information
Principal Investigator: Giuseppe Frazzitta, MD Department of Parkinson's disease, Movement Disorders and Brain Injury Rehabilitation, "Moriggia-Pelascini" Hospital - Via Pelascini, 3, 22015, Gravedona ed Uniti, Como, Italy
More Information
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Ospedale Generale Di Zona Moriggia-Pelascini
ClinicalTrials.gov Identifier: NCT03478124    
Other Study ID Numbers: NPsy-PSP
First Posted: March 27, 2018    Key Record Dates
Last Update Posted: March 27, 2018
Last Verified: March 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Supranuclear Palsy, Progressive
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Ophthalmoplegia
 Ocular Motility Disorders
Cranial Nerve Diseases
Tauopathies
Neurodegenerative Diseases
Paralysis
Neurologic Manifestations
Eye Diseases